The abstract is read at the publisher; the summary is JClub's.
In advanced biliary tract cancer, ctDNA profiling detects actionable genomic alterations faster (8 vs. 27 days) and more often (90% vs. 50%) than tissue, with high concordance.
- Why it matters: Tissue sampling can be slow or insufficient in advanced disease, limiting timely identification of actionable targets and delaying ctDNA-directed decision-making.
- What they did: The study compared ctDNA versus tissue genomic profiling in advanced biliary tract cancer, reporting time to detection and the frequency of actionable alterations, alongside concordance between methods.
- The result: ctDNA profiling shows clinical validity and supports an access case for future prospective ctDNA-directed trials, enabling faster and more frequent target detection than tissue.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.